Novartis: production capacity agreement with Roche
(CercleFinance.com) - Novartis announced on Thursday that it will provide Roche with additional manufacturing capacity for the production of its rheumatoid arthritis treatment Actemra/RoActemra.
The agreement comes as a Phase III clinical trial is currently evaluating the efficacy of Actemra/RoActemra in the treatment of severe Covid-19 related pneumonia.
Initial results are expected in early summer.
Under the terms of the agreement between both groups, manufacturing processes for the drug will be transferred to a Novartis facility in Singapore in Q2.
The agreement covers not only the transfer of technology, but also the mechanism for validating the manufacturing processes.
This is not the first time that Novartis has signed such a partnership. In January this year, the biopharmaceutical group signed an agreement with Germany's BioNtech to expand production capacity for its Covid vaccine from its plant in Stein, Switzerland.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
The agreement comes as a Phase III clinical trial is currently evaluating the efficacy of Actemra/RoActemra in the treatment of severe Covid-19 related pneumonia.
Initial results are expected in early summer.
Under the terms of the agreement between both groups, manufacturing processes for the drug will be transferred to a Novartis facility in Singapore in Q2.
The agreement covers not only the transfer of technology, but also the mechanism for validating the manufacturing processes.
This is not the first time that Novartis has signed such a partnership. In January this year, the biopharmaceutical group signed an agreement with Germany's BioNtech to expand production capacity for its Covid vaccine from its plant in Stein, Switzerland.
Copyright (c) 2021 CercleFinance.com. All rights reserved.